Nitric oxide: Redox balance, protein modification and therapeutic potential in cardiovascular system

IIOAB Journal

Volumn 2, Issue 6, 2011, Pages 29-38

  Mattapally, Saidulu ^a   Banerjee, Sanjay Kumar ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Cardiovascular; Nitric oxide; Nitrosylation; Pharmacology; Redox balance

Indexed keywords

ACETYLSALICYLIC ACID; ATACIGUAT; ATORVASTATIN; CAPTOPRIL; CINACIGUAT; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NEBIVOLOL; NEURONAL NITRIC OXIDE SYNTHASE; NICORANDIL; NITRIC OXIDE; NITRIC OXIDE DONOR; REACTIVE OXYGEN METABOLITE;

ANGINA PECTORIS; ANGIOGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; DRUG DESIGN; HEART CONTRACTION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; NONHUMAN; OXIDATION REDUCTION STATE; PATHOPHYSIOLOGY; PROTEIN MODIFICATION; REGULATORY MECHANISM; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 80052726333     PISSN: 09763104     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Katsuki S, Arnold WP, Murad F. [1977] Effect of sodium nitroprusside, nitroglycerin and sodium azide on levels of cyclic nucleotides and mechanical activity of various tissues. J Cyclic Nucl Res 3: 239-247
2. SoRelle R. [1998] Nobel Prize Awarded to Scientists for Nitric Oxide Discoveries. Circulation 98: 2365-2366.
3. Gruetter CA, Barry BK, McNamara DB, Gruetter DY, Kadowitz PJ, Ignarro L. [1979] Relaxation of bovine coronary artery and activation of coronary arterial guanylatecyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. J Cyclic Nucleotide Res 5: 211-224.
4. Kourie JI. [1998] Interaction of reactive oxygen species with ion transport mechanisms. Am J Physiol 275:C1-C24.
5. Nordberg J, Arnér ES. [2001] Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med 31:1287-1312.
6. Powis G, Briehl M, Oblong J. [1995] Redox signalling and the control of cell growth and death. Pharmacol Ther 68:149-173.
7. Banerjee SK, Mukherjee PK and Maulik SK. [2003] The antioxidant effect of garlic. The good, the bad and the ugly. Phytother Res 17: 1-10.
8. Banerjee SK, Maulik SK. [2002] Effect of garlic on cardiovascular disorders: a review. Nutr J 1:4
9. Heistad DD, Wakisaka Y, Miller J, Chu Y, Pena-Silva R. [2009] Novel aspects of oxidative stress in cardiovascular diseases. Circ J 73:201-207.
10. Simionescu M. [2009] Cellular dysfunction in inflammatory-related vascular disorders' review series. The inflammatory process. J Cell Mol Med 13:4291-4292.
11. Zalba G, Fortuño A, San José G, Moreno MU, Beloqui O, Díez J. [2007] Oxidative stress, endothelial dysfunction and cerebrovascular disease. Cerebrovasc Dis 1: 24-29.
12. Das KCY, Lewis M, White CW. [1997] Elevation of manganese super oxidedismutase gene expression by thioredoxin. Am J Respir Cell Mol Biol 17:713-726.
13. Moncada S, Palmer RM, Higgs EA. [1991] Nitric oxide: physiology, pathophysiology and pharmacology Chemical Biolog. Pharmacol Rev 43: 109-142.
14. Godecke A, Heinicke T, Kamkin A, Kiseleva I, Strasser RH, et al. [2001] Inotropic response to beta-adrenergic receptor stimulation and antiadrenergic effect of ACh in endothelial NO synthase-deficient mouse hearts. J Physiol 532: 195-204.
15. Xu KY, Huso DL, Dawson TM, Bredt DS, Becker LC. [1999] Nitric oxide synthase in cardiac sarcoplasmic reticulum. Proc Natl Acad Sci USA 96:657-662.
16. Xu KY, Kuppusamy SP, Wang JQ, Li H, Cui H, et al. [2003] Nitric oxide protects cardiac sarcolemmal membrane enzyme function and ion active transport against ischemia-induced inactivation. J Biol Chem 278:41798-41803.
17. Seddon M, Melikian N, Dworakowski R, Shabeeh H, Jiang B, Byrne J, et al. [2009] Effects of neuronal nitric oxide synthase on human coronary artery diameter and blood flow in vivo. Circulation 119:2656-2662.
18. Hood JD, Meininger CJ, Ziche M, Granger HJ.[1998] VEGF upregulates eNOS messager, protein, and NO production in human endothelial cells. Am J Physiol 274:H1054-H1058.
19. Babaei S, Teichert-Kuliszewska K, Monge JC, Mohamed F, Bendeck MP, Stewart DJ. [1998] Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor. Circ Res 82:1007-1015.
20. Beckman JS, Ye YZ, Anderson PG, Chen J, Accavitti MA, Tarpey MM, White CR. [1994] Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe Seyler 375:81-88.
21. Graham A, Hogg N, Kalyanaraman B, O-Leany V, Darley-Usmar V, Moncada S. [1993] Peroxynitrite modification of low-density lipoprotein leads to recognition by the macrophage scavenger receptor. FEBS Lett 330: 181-185.
22. Panza JA, Garcia CE, Kilcoyne CM, Quyyumi AA, Cannon RO. [1995] Impaired endothelium dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 91:1732-1738.
23. Treasure CB, Klein JL, Vita JA, Manoukian SV, Renwick GH, Selwyn AP, Ganz P, Alexander RW. [1993] Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 87: 86-93.
24. Higashi Y, Oshima T, Ozono R, Watanabe M, Matsuura H, Kajiyama G. [1995] Effects of L-arginine infusion on renal hemodynamics in patients with mild essential hypertension. Hypertension 25:898-902.
25. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, Michelson AD. [1997] Nitricoxide released from activated platelets inhibits platelet recruitment. J Clin Invest 100: 350-356.
26. Walter U, Gambaryan S. [2009] cGMP and cGMP-dependent protein kinase in platelets and blood cells. Handb Exp Pharmacol 191:533-548.
27. Friebe A, Koesling D. [2009] The function of NO-sensitive guanylylcyclase: what we can learn from genetic mouse models. Nitric Oxide 21:149-156.
28. Li Z, Xi X, Gu M, Feil R, Ye RD, Eigenthaler M, Hofmann F, Du X. [2003] A Stimulatory Role for cGMP-Dependent Protein Kinase in Platelet Activation Cell 112: 77-86.
29. Foster MW, McMahon TJ, Stamler JS. [2003] S-nitrosylation in health and disease. Trends Mol Med 9: 160-168.
30. Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS. [2005] Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol 6: 150-166.
31. Sayed N, Kim DD, Fioramonti X, Iwahashi T, Duran WN, Beuve A. [2008] Nitroglycerin-induced S-nitrosylation and desensitization of soluble guanylylcyclase contribute to nitrate tolerance. Circ Res 103: 606-614.
32. Murray CI, Gebska MA, Haile A, Zhang M, Kass DA, Champion HC, Van Eyk JE. [2008] cGMP specific phosphodiesterase type 5A activity is regulated by S-nitrosylation at Cys 181. Circulation 118:S415.
33. Ravi K, Brennan LA, Levic S, Ross PA, Black SM. [2004] S-nitrosylation of endothelial nitric oxide synthase is associated with monomerization and decreased enzyme activity. Proc Natl Acad Sci USA 101: 2619-2624.
34. Liu L. [2004] Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock. Cell 116:617-628.
35. Lima B. [2009] Endogenous S-nitrosothiols protect against myocardial injury. Proc Natl Acad Sci USA 106: 6297-6302.
36. Sengupta R, Ryter SW, Zuckerbraun BS, Tzeng E, Billiar TR, Stoyanovsky DA. [2007] Thioredoxin catalyzes the denitrosation of low-molecular mass and protein S-nitrosothiols. Biochemistry 46: 8472-8483.
37. Stoyanovsky DA, Tyurina YY, Tyurin VA, Anand D, Mandavia DN, et al. [2005] Thioredoxin and lipoic acid catalyze the denitrosation of low molecular weight and protein S-nitrosothiols. J Am Chem Soc 127:15815-15823.
38. Benhar M, Forrester MT, Hess DT, Stamler JS. [2008] Regulated protein denitrosylation by cytosolic and mitochondrial thioredoxins. Science 320: 1050-1054.
39. Lubos E, Handy DE, Loscalzo J. [2008] Role of oxidative stress and nitric oxide in atherothrombosis. Front Biosci1 3: 5323-5344.
40. Thomas SR, Witting PK, Drummond GR. [2008] Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 10: 1713-1765.
41. Griscavage JM, Hobbs AJ, Ignarro LJ. [1995] Negative modulation of nitric oxide synthase by nitric oxide and nitroso compounds. Adv Pharmacol 34:215-234.
42. Balligand JL, Feron O, Dessy C. [2009] eNOS Activation by Physical Forces: From Short-TermRegulation of Contraction to Chronic Remodeling of Cardiovascular Tissues. Physiol Rev 89: 481-534.
43. Fulton D, Gratton JP, McCabe TJ. [1999] Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399: 597-601.
44. Harris MB, Ju H, Venema VJ, Liang H. [2001] Reciprocal Phosphorylation and Regulation of Endothelial Nitric-oxide Synthase in Response to Bradykinin Stimulation. J Biol Chem 276: 16587-16591.
45. Kou R., Greif D, Michel T. [2002] Dephosphorylation of Endothelial Nitric-oxide Synthase by Vascular Endothelial Growth Factor. J Biol Chem 277:29669-29673.
46. Crabtree MJ, Smith CL, Lam G, Goligorsky MS, Gross SS. [2008] Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucose-elicited changes in NO vs. superoxide production by eNOS. Am J Physiol Heart Circ Physiol 294: H1530-H1540.
47. Forstermann U, Munzel T. [2006] Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113: 1708-1714.
48. Moen AL, Kass DA. [2006] Tetrahydrobiopterin and cardiovascular disease. Arterioscler Thromb Vasc Biol 26: 2439-2444.
49. Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, et al. [1998] Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors.Proc, Natl, Acad, Sci and USA 95: 9220-9225.
50. Wever RM, van Dam T, van Rijn HJ, de Groot F, Rabelink TJ. [1997] Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. Biochem Biophys Res Commun 237: 340-344.
51. Sugiyama T, Levy BD, Michel T. [2009] Tetrahydrobiopterin recycling, a key determinant of endothelial nitric-oxide synthase-dependent signaling pathways in cultured vascular endothelial cells. J Biol Chem 284: 12691-12700.
52. Kurioka S, Koshimura K, Murakami Y, Nishiki M, Kato Y. [2000] Reverse correlation between urine nitric oxide metabolites and insulin resistance in patients with type 2 diabetes mellitus. Endocr J 47: 77-81.
53. Node K, Kitakaze M, Yoshikawa H, Kosaka H, Hori M. [1997] Reduced plasma concentrations of nitrogen oxide in individuals with essential hypertension. Hypertension 30: 405-408.
54. Piatti P, Di Mario C, Monti L.D, Fragasso G, Sgura F, Caumo A. [2003] Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation 108: 2074-2081.
55. Tanaka S, Yashiro A, Nakashima Y, Nanri H, Ikeda M, Kuroiwa A. [1997] Plasma nitrite/nitrate level is inversely correlated with plasma low-density lipoprotein cholesterol level. Clin Cardiol 20: 361-365.
56. Cooke JP. [2005] ADMA: its role in vascular disease. Vasc Med 10: S11-S17.
57. Cook S. [2006] Coronary artery disease, nitric oxide and oxidative stress: the "Yin-Yang" effect, a Chinese concept for a worldwide pandemic. Swiss Med Wkly 136: 103-113.
58. Schmidt HH, Schmidt PM, Stasch JP. [2009] NO- and haem-independent soluble guanylatecyclase activators. Handb Exp Pharmacol 191:309-339.
59. Nakata S, Tsutsui M, Shimokawa H, Suda O, Morishita T, Shibata K [2008]. Spontaneous myocardial infarction in mice lacking all nitric oxide synthase isoforms. Circulation 117: 2211-2223.
60. Simko F, Pechanova O, Pelouch V, Krajcirovicova K, Celec P, et al. [2010] Continuous light and L-NAME-induced left ventricular remodelling: different protection with melatonin and captopril. J Hypertens 28:S13-S18.
61. Maron DJ, Fazio S, Linton MF. [2000] Current perspectives on statins. Circulation 101: 207-213.
62. Takemoto M, Liao JK. [2001] Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21: 1712-1719.
63. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK. [1998] Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 95: 8880-8885.
64. Chen H, Ikeda U, Shimpo M, Ikeda M, Minota S, Shimada K. [2000] Fluvastatin upregulates inducible nitric oxide synthase expression in cytokine-stimulated vascular smooth muscle cells. Hypertension 36: 923-928.
65. Shimpo M, Ikeda U, Maeda Y, Ohya K, Murakami Y, Shimada K. [2000] Effects of aspirin-like drugs on nitric oxide synthesis in rat vascular smooth muscle cells. Hypertension 35:1085-1091.
66. Bussmann WD, Passek D, Seidel W, Kaltenbach M. [1981] Reduction of CK and CK-MB indexes of infarct size by intravenous nitroglycerin. Circulation 63: 615-622.
67. Jugdutt BI, Warnica JW. [1988] Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage, and infarct location. Circulation 78: 906-919.
68. Rapaport E. [1985] Influence of long-acting nitrate therapy on the risk of reinfarction, sudden death, and total mortality in survivors of acute myocardial infarction. Am Heart J 110: 276-280.
69. Ishikawa K, Kanamasa K, Ogawa I, Takenaka T, Naito T, Kamata N. [1996] Long-term nitrate treatment increases cardiac events in patients with healed myocardial infarction. Secondary Prevention Group. Jpn Circ J 60: 779-788.
70. Kanamasa K, Hayashi T, Takenaka T, Kimura A, Ikeda A, Ishikawa K. [2000] Chronic use of continuous dosing of long-term nitrates does not prevent cardiac events in patients with severe acute myocardial infarction. Cardiology 94: 139-145.
71. IONA Study Group. [2002] Effect of nicorandil on coronary events in patients with stable angina: The Impact OfNicorandil in Angina (IONA) randomised trial. Lancet 359: 1269-1275.
72. Kamp O, Metra M, Bugatti S, Bettari L, Dei Cas A, Petrini N, Dei Cas L. [2010] Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release. Drugs 70:41-56.
73. DiStilo A, Chegaev K, Lazzarato L, Fruttero R, Gasco A, Rastaldo R, Cappello S. [2009] Effects of nitric oxide donor antioxidants containing the phenol vitamin E substructure and a furoxan moiety on ischemia/reperfusion injury. Arzneimittelforschung 59:111-116.